Danielle Ternyila


Camrelizumab/Apatinib Shows Promising Activity in Second-Line Esophageal Squamous Cell Carcinoma

January 15th 2021

January 15, 2021 - A novel combination comprised of camrelizumab and apatinib was found to have promising clinical efficacy with an acceptable safety profile when used as a second-line treatment in patients with esophageal squamous cell carcinoma.

Disease Recurrence Similar Between Tamoxifen, Anastrozole in Postmenopausal Women With DCIS

December 10th 2020

December 9, 2020 - Treatment with tamoxifen versus anastrozole did not yield any significant difference in terms of disease recurrence in postmenopausal women with locally excised ductal carcinoma in situ but understanding associated toxicities can inform care decisions.

Higher Dose of CPX-351 Linked With Prolonged Hematologic Recovery in AML

December 9th 2020

CPX-351, when given at higher doses in induction cycles 1 and 2, significantly prolonged hematologic recovery in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Umbralisib/Ublituximab Plus Venetoclax Induces High Objective Response Rate in Relapsed/Refractory CLL

December 8th 2020

December 8, 2020 - The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.

CELMoD CC-92480/Dexamethasone Combo Shows Early Activity in Relapsed/Refractory Myeloma

December 6th 2020

CC-92480, a novel oral cereblon E3 ligase modulator agent, plus dexamethasone demonstrated immunomodulatory activity across all dose levels examined in patients with relapsed/refractory multiple myeloma, according to data from the first portion of the ongoing phase 1 CC-92480-MM-001 trial presented during the 2020 ASH Annual Meeting & Exposition.

Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis

December 5th 2020

December 5, 2020 - The addition of navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

JAK Inhibitors Continue to Shape Myelofibrosis Paradigm

November 23rd 2020

 John O. Mascarenhas, MD, discusses how the positioning of JAK inhibitors in myelofibrosis has shifted, and also pointed to new agents under investigation.

Frontline Lenvatinib/Everolimus Combo Is Active in Non-Clear Cell RCC

November 6th 2020

The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.

Palliative Care Study Suggests Benefits for Patients With Cervical Cancer

April 9th 2020

Alexandra S. Bercow, MD, discusses the implications of research showing that patients with advanced-stage cervical cancer who received palliative care consultations underwent the same level of treatment but had shorter, less acute, and fewer hospital stays than their counterparts who were not given such referrals.

Expert Highlights Multitargeted Treatments in Hematologic Malignancies

March 18th 2020

David S. Hong, MD, discusses the burgeoning role of multitargeted therapeutics in patients with hematologic malignancies.

Analysis Yields Potential New Precision Medicine Path in mHSPC

March 17th 2020

Anis Hamid, MBBS, discusses the analysis of genomic profiling from the phase III CHAARTED trial, and the burgeoning potential of precision medicine in metastatic hormone sensitive prostate cancer.

Unmet Needs Remain in GVHD, But Novel Approaches on Horizon

March 1st 2020

Corey S. Cutler, MD, MPH, discusses how physicians can optimize treatment management in patients with both acute and chronic graft-versus-host-disease.

Acalabrutinib Approval Leads Frontline Advances in CLL

February 29th 2020

A number of therapeutic options have become available in the frontline setting for patients with chronic lymphocytic leukemia, most recently the second-generation BTK inhibitor acalabrutinib.

Park Touts Further Developments, Unmet Needs With CAR T-Cell Therapy in ALL

February 28th 2020

Jae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.

Expert Highlights Emergence of Mosunetuzumab in Non-Hodgkin Lymphoma

February 26th 2020

Stephen J. Schuster, MD, discusses promising findings and next steps for mosunetuzumab in patients with relapsed/refractory non-Hodgkin lymphoma.

Pasireotide Does Not Decrease Risk of GI Toxicity or Acute GVHD Following HSCT

February 24th 2020

Anthony D. Sung, MD, discusses the findings from the phase II trial of pasireotide as a method to prevent gastrointestinal toxicity and acute graft-versus-host-disease in patients who undergo allogeneic hematopoietic stem cell transplant.

KTE-X19 Poised to Have Promising Future in MCL Paradigm

February 23rd 2020

David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.

Expert Highlights Remaining Diagnostic Challenges With TA-TMA

February 22nd 2020

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.

Expert Highlights Luspatercept Benefit as Treatment of Anemia in Myelofibrosis

February 21st 2020

Aaron Gerds, MD, discusses data presented at the 2019 ASH Annual Meeting highlighting luspatercept as a treatment of anemia in patients with myelofibrosis.

Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand

February 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.